'On consolidated basis
Quarter ended December 2025 compared with Quarter ended December 2024.
Net sales (including other operating income) of Cipla has increased 0.02% to Rs 7074.48 crore. Sales of Phamaceuticals segment has gone down 0.46% to Rs 6,746.40 crore (accounting for 94.65% of total sales). Sales of New Ventures segment has gone up 11.77% to Rs 381.48 crore (accounting for 5.35% of total sales). Inter-segment sales rose Rs 46.17 crore to Rs 53.40 crore.
Profit before interest, tax and other unallocable items (PBIT) has slumped 38.73% to Rs 1,183.05 crore. PBIT of Phamaceuticals segment fell 40.59% to Rs 1,122.26 crore (accounting for 94.86% of total PBIT). PBIT of New Ventures segment rose 45.19% to Rs 60.79 crore (accounting for 5.14% of total PBIT).
PBIT margin of Phamaceuticals segment fell from 27.87% to 16.63%. PBIT margin of New Ventures segm...
Pleaselogin & subscribe to view the full report.
More Reports
|
|